Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic Reactions in Patients at Risk of Anaphylaxis

NCT07045701 is registered in ClinicalTrials.gov with Nasus Pharma as lead sponsor.

NCT NCT07045701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07045701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic Reactions in Patients at Risk of Anaphylaxis
Lead sponsor
Nasus Pharma
Phase
Phase 2/3
Overall status
Enrolling by invitation
Start date
June 12, 2025
Completion date
July 12, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaphylaxis food